Rigor Reviewed

Rigor-Reviewed Manuscript

AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.

Name: Αlpha¹ Rigor Record — AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Item: AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Rating: 59
Author: Αlpha¹

Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 1★ (Critical), 0 critical, 5 high issues for “AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

1 / 5

Critical — serious problems across many checks

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×4−2★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 3 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced7 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 3 randomized controlled trial with rigorous design, clear ethical approvals, and transparent reporting. The main weaknesses are the vague data availability statement, lack of explicit power calculation, and absence of named statistical software and reporting guideline.

Both reviewers classified the study as interventional and agreed on all dimension statuses; no divergence to reconcile. The statistics verification recomputed only a subset of tests (5 total, 4 consistent, 1 unspecified inconsistency), so the paper's statistics should not be considered fully verified. The integrity check noted retrospective registration of a related trial (NCT03769116), which is a transparency concern but not part of the eight dimensions.

5 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks. 1 printed percentage that does not match its own count.

4 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on DMD, current treatments, and early-phase delandistrogene moxeparvovec studies, acknowledging both the unmet need and the promising early results. The rationale for the trial is clearly stated: to assess efficacy and safety in a larger phase 3 setting. Limitations of prior research (e.g., small sample sizes, short follow-up) are implicitly addressed by the trial's design, though not explicitly discussed as limitations of prior work.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on DMD pathology, existing treatments, and early-phase gene therapy studies, and logically links this to the trial's objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“Duchenne muscular dystrophy (DMD) is caused by pathogenic variants in the X-linked DMD gene, leading to an absence of functional dystrophin and continuous muscle damage, beginning from birth.”

direct quote[Introduction, paragraph 3]

“Early-phase clinical studies demonstrated a manageable safety profile for delandistrogene moxeparvovec. In these studies, delandistrogene moxeparvovec micro-dystrophin expression was robust with sarcolemmal localization up to 60 weeks after treatment and demonstrated a sustained functional stabilization through 4 years in four males with DMD”